New England Biolabs Canada

Product Pathways - Cell Cycle / Checkpoint

DYRK2 (D9A3K) Rabbit mAb #11921

Item# Description List Price Web Price Qty
11921S DYRK2 (D9A3K) Rabbit mAb - 100 µl $372.00
*On-line ordering is for Canadian customers only. Web pricing is applicable only to orders placed online at
Application Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W Human, Mouse, Rat, Hamster, Monkey Endogenous 60, 66 Rabbit IgG

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting


Specificity / Sensitivity

DYRK2 (D9A3K) Rabbit mAb recognizes endogenous levels of total DYRK2 protein. The antibody recognizes both known isoforms, 66 and 60 kDa, of DYRK2.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly545 of human DYRK2 protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using DYRK2 (D9A3K) Rabbit mAb.


The DYRK family includes several dual-specificity tyrosine-phosphorylated and regulated kinases capable of phosphorylating proteins at both Tyr and Ser/Thr residues (1). The DYRK family was identified based on homology to the yeast Yak1 (2) and the Drosophila minibrain (mnb) kinases (3). Seven mammalian isoforms have been discovered, including DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4, and DYRK4B. Differences in substrate specificity, expression, and subcellular localization are seen across the DYRK family (4,5). All DYRK proteins have a Tyr-X-Tyr motif in the catalytic domain activation loop; phosphorylation of the second Tyr residue (e.g. Tyr312 of DYRK1A) is necessary for kinase activity. DYRKs typically autophosphorylate the Tyr residue within their activation loop, but phosphorylate substrates at Ser and Thr residues (1,6).

DYRK2 is thought to play a role in checkpoint control of the cell cycle. DYRK2 can phosphorylate p53 at Ser46 following cellular damage, leading to activation of the apoptotic response (7). Research studies have demonstrated overexpression of DYRK2 in esophageal and lung adenocarcinomas (8), with DYRK2 expression levels acting as a potential predictor of chemotherapy treatment outcomes in non-small cell lung cancer (9).

  1. Becker, W. and Joost, H.G. (1999) Prog. Nucleic Acid Res. Mol. Biol. 62, 1-17.
  2. Garrett, S. and Broach, J. (1989) Genes Dev. 3, 1336-1348.
  3. Tejedor, F. et al. (1995) Neuron 14, 287-301.
  4. Kentrup, H. et al. (1996) J. Biol. Chem. 271, 3488-3495.
  5. Becker, W. et al. (1998) J. Biol. Chem. 273, 25893-25902.
  6. Lochhead, P.A. et al. (2005) Cell 121, 925-936.
  7. Taira, N. et al. (2007) Mol Cell 25, 725-38.
  8. Miller, C.T. et al. (2003) Cancer Res 63, 4136-43.
  9. Yamashita, S. et al. (2009) Anticancer Res 29, 2753-7.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Toll Free: 1-800-387-1095

Fax: 1-800-563-3789

About NEBTerms of Sale Web Discount Shipping Information Web Site Disclaimer Privacy Policy NEB USA Cell Signaling Technology Sitemap
Contents ¬©New England Biolabs Ltd.  New England Biolabs Ltd. is the exclusive Canadian distributor for Cell Signaling Technology, Inc.  New England Biolabs, Inc. is an ISO 9001 certified company.

Search another product:


Item has been added to the cart


Item has been added to the favourites